Bayesian Capital Management, LP Genmab A/S Transaction History

Bayesian Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$26.43 - $32.77 $302,253 - $374,757	11,436 New	11,436 $342,000
Q4 2022 Feb 14, 2023	BUY	$33.8 - $47.06 $421,350 - $586,649	12,466 New	12,466 $528,000
Q2 2022 Aug 15, 2022	SELL	$26.83 - $38.57 $320,994 - $461,451	-11,964 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$30.95 - $39.68 $370,285 - $474,731	11,964 New	11,964 $433,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.